Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2013 by Chinese PLA General Hospital.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Junle Liu, Chinese PLA General Hospital Identifier:
First received: August 21, 2013
Last updated: September 7, 2013
Last verified: September 2013

Hip fractures incidence grows rapidly with the aging of the population. After indicated surgical treatment, hip fracture patients experience high rates of postoperative complications, postoperative delirium (PD), postoperative cognitive dysfunction (POCD), leading to poor postoperative recovery during hospitalization, which can cause disability, distress for both patients and their families, are associated with other medical complications and account for significant additional health care costs. We currently use dexmedetomidine in elderly patients with hip fractures undergoing hip hemi-arthroplasty in order to improve postoperative recovery and prevent and treating PD and POCD.

Dexmedetomidine is a drug used for sedation in critically ill patients that provides some pain relief and controls the bodies response to stress. The sedation produced by dexmedetomidine appears more similar to natural sleep than any other drug used for anesthesia and postoperative sedation. Data suggesting that dexmedetomidine can prevent delirium following cardiac surgery and the developing understanding of the causes of PD and POCD suggest that dexmedetomidine will be particularly effective.

Condition Intervention Phase
Femoral Neck Fractures
Postoperative Complications
Inflammatory Response
Postoperative Delirium
Postoperative Cognitive Dysfunction
Procedure: hip arthroplasty
Drug: Total Intravenous Anesthesia and Peripheral nerve blocks
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: The Effect of Dexmedetomidine on Postoperative Recovery in Elderly Patients With Femoral Neck Fracture Undergoing Hip Hemi-arthroplasty

Resource links provided by NLM:

Further study details as provided by Chinese PLA General Hospital:

Primary Outcome Measures:
  • postoperative cognitive dysfunction(POCD) [ Time Frame: 7days ]
    POCD is assessed by Montreal Cognitive Assessment(MoCA), which was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration,executive functions, memory, language,visuoconstructional skills, conceptual thinking,calculations, and orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points; a score of 26 or above is considered normal.

Secondary Outcome Measures:
  • Postoperative recovery [ Time Frame: 7days ]
    The postoperative recovery is assessed by the Post-operative Quality Recovery Scale (PQRS),which is a research tool designed to measure postoperative quality of recovery in multiple domains and over multiple time periods. Recovery domains include physiological, emotive (depression and anxiety), nociceptive (pain and nausea), cognitive, activities of daily living (ADL), and overall patient perspective (including satisfaction).

  • Postoperative Delirium(PD) [ Time Frame: 72 hours ]
    The postoperative Delirium is assessed by the Confusion Assessment Method (CAM)

Other Outcome Measures:
  • postoperative complications [ Time Frame: 7 days ]
  • perioperative opioid consumption [ Time Frame: 3 days ]
    Intraoperative and postoperative opioid consumption were calculated between the two groups.

  • IL-6 and C-reacting protein [ Time Frame: 7 days ]
  • MB isoenzyme of creatine kinase and blood sugar [ Time Frame: 7 days ]

Estimated Enrollment: 80
Study Start Date: September 2013
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Dexmedetomidine
Dexmedetomidine in dex group is administered as 1ug/kg by intravenous infusion 10 min and then 0.6 ug/kg until 30 minutes before the operation finishes.
Procedure: hip arthroplasty
Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.
Drug: Total Intravenous Anesthesia and Peripheral nerve blocks
Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol
Placebo Comparator: Saline
Participants in con group receive placebo(saline) as the same dose at the same time as dex group.
Procedure: hip arthroplasty
Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.
Drug: Total Intravenous Anesthesia and Peripheral nerve blocks
Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol


Ages Eligible for Study:   75 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Age > 75years old
  • Patients with femoral neck fractures
  • Undergoing hip hemi-arthroplasty surgery
  • American Society of Anesthesiologists (ASA) physical status II-IV
  • MoCA being more than 23

Exclusion Criteria

  • Patient refusal to participate in the study
  • Patient refusal or failure of regional block
  • allergic to local anesthetics or general anesthetics
  • history of opioid dependence
  • contraindications to nerve blocks (coagulation defects, infection at puncture site, preexisting neurological deficits in the lower extremities)
  • current severe psychiatric disease or alcoholism or drug dependence
  • severe visual or auditory disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01934049

Contact: zhang hong, ph.d 0086-10-66937462
Contact: yuan weixiu, ph.d

Anesthesia and Operation Center, Chinese People's Liberation Army General Hospital Recruiting
Beijing, China, 100853
Contact: Zhang Hong, ph.d    0086-10-66937462   
Contact: Yuan Weixiu, Ph.d    0086-10-66938052   
Sub-Investigator: Gong Maowei, MD         
Sub-Investigator: Zhao Ying, MD         
Sponsors and Collaborators
Chinese PLA General Hospital
Study Chair: zhang hong, ph.d Anesthesia and Operation Center, Chinese People's Liberation Army General Hospital
  More Information

Responsible Party: Junle Liu, Principal Investigator, Chinese PLA General Hospital Identifier: NCT01934049     History of Changes
Other Study ID Numbers: Dex-THR
Study First Received: August 21, 2013
Last Updated: September 7, 2013

Additional relevant MeSH terms:
Fractures, Bone
Postoperative Complications
Femoral Neck Fractures
Wounds and Injuries
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Neurocognitive Disorders
Mental Disorders
Pathologic Processes
Hip Fractures
Femoral Fractures
Hip Injuries
Leg Injuries
Central Nervous System Depressants
Physiological Effects of Drugs
Hypnotics and Sedatives
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents processed this record on April 28, 2017